IMUNON, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.44 USD | 0.00% |
|
+23.08% | +111.76% |
| Apr. 18 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
| Apr. 18 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 38.91 | 26.6 | 46.74 | 10.04 | 6.392 | 13.54 | - | - |
| Enterprise Value (EV) 1 | 38.91 | 26.6 | 46.74 | 10.04 | 6.392 | 13.54 | 13.54 | 13.54 |
| P/E ratio | -2.22 x | -1.06 x | -2.11 x | -0.27 x | -0.31 x | -0.64 x | -0.84 x | -0.83 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 77.8 x | 53.2 x | 93.5 x | 20.1 x | - | - | - | 3.44 x |
| EV / Revenue | 77.8 x | 53.2 x | 93.5 x | 20.1 x | - | - | - | 3.44 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | -0.59 x | -0.39 x | -0.3 x |
| FCF Yield | - | - | - | - | - | -170% | -259% | -332% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,517 | 2,495 | 5,771 | 7,434 | 9,399 | 9,400 | - | - |
| Reference price 2 | 25.65 | 10.66 | 8.100 | 1.350 | 0.6800 | 1.440 | 1.440 | 1.440 |
| Announcement Date | 3/25/20 | 3/19/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.5 | 0.5 | 0.5 | 0.5 | - | - | - | 3.933 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.56 | -18.49 | -21.01 | -24.92 | -21.03 | -22.69 | -26.49 | -36.75 |
| Operating Margin | -4,113% | -3,697.2% | -4,201.4% | -4,984.4% | - | - | - | -934.32% |
| Earnings before Tax (EBT) 1 | -18.67 | -23.33 | -22.15 | -37.46 | -20.8 | -22.96 | -26.89 | -36.8 |
| Net income 1 | -16.85 | -21.48 | -20.77 | -35.9 | -19.52 | -22.96 | -26.89 | -36.8 |
| Net margin | -3,370.4% | -4,296.8% | -4,153.8% | -7,179.6% | - | - | - | -935.59% |
| EPS 2 | -11.55 | -10.05 | -3.830 | -5.030 | -2.160 | -2.267 | -1.710 | -1.730 |
| Free Cash Flow 1 | - | - | - | - | - | -23 | -35 | -45 |
| FCF margin | - | - | - | - | - | - | - | -1,144.07% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/25/20 | 3/19/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.125 | 0.125 | 0.125 | 0.125 | 0.125 | 0.125 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -5.062 | -5.491 | -5.842 | -5.978 | -6.174 | -6.927 | -5.684 | -5.474 | -3.904 | -5.968 | -5.359 | -5.603 | -5.6 | -5.965 |
| Operating Margin | -4,049.6% | -4,392.54% | -4,673.6% | -4,782.4% | -4,939.2% | -5,541.75% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -5.411 | -5.605 | -10.47 | -6.043 | -6.148 | -14.8 | -5.591 | -5.559 | -3.477 | -6.168 | -5.426 | -5.77 | -5.633 | -6.098 |
| Net income 1 | -5.411 | -4.221 | -10.47 | -6.043 | -6.148 | -13.23 | -5.591 | -5.559 | -3.477 | -4.888 | -5.426 | -5.77 | -5.633 | -6.098 |
| Net margin | -4,328.8% | -3,376.85% | -8,379.2% | -4,834.4% | -4,918.4% | -10,585.95% | - | - | - | - | - | - | - | - |
| EPS 2 | -0.9000 | -3.620 | -1.820 | -0.8700 | -0.8700 | -1.610 | -0.6800 | -0.6100 | -0.3700 | -0.5200 | -0.5667 | -0.6033 | -0.5867 | -0.5100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/28/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | - | -23 | -35 | -45 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | 1 | 1 | 1 |
| Capex / Sales | - | - | - | - | - | - | - | 25.42% |
| Announcement Date | 3/25/20 | 3/19/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.44
USD
Average target price
12
USD
Spread / Average Target
+733.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +111.76% | 13.54M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IMNN Stock
- Financials Imunon, Inc.
